公司資料
ALXN 股價、新聞與催化劑
- 股票代碼:
- ALXN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for ALXN.
公司概覽
業務概覽
Alexion Pharmaceuticals was a rare-disease biotechnology company known for complement biology and ultra-rare disease therapies before being acquired by AstraZeneca. Its business centered on high-value specialty medicines for severe, uncommon conditions.
所在地與產業分類
Alexion was headquartered in the United States and listed on NASDAQ before its acquisition. It occupied a rare-disease biopharma position with global commercial reach.
商業模式特徵
The company relied on specialty drug commercialization, rare-disease access, and the durability of high-value orphan therapies. Investors historically watched launch performance, label breadth, and the sustainability of its rare-disease franchise.
生技產業定位
Alexion was a premium rare-disease biotech name with a strong commercial identity. It stood out because of its orphan-drug focus and the way a narrow portfolio could still create a large market value.
未來催化劑
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。